GLP-1 medications are not FDA-approved specifically for PMOS
References Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R
Perhaps the FDAs pilot PRIME initiative on a pathway to approving excipients independent of associated bioactive molecules will provide new options for enhancer selection
The schematic representations refer to the inhibitors that belong to: a-d) Kunitz family (BPTI-type), e-i) Kazal family (PSTI-type), j) inhibitor from Streptomyces, k) Kunitz-type family from soybean, l) Bowman-Birk family, m) potato type I family, n) potato type II family Cysteine residues in homologous proteins (those of common ancestry) are very conservative according to PAM 250 scoring matrix (Fig 4)
Ingredients: Each capsule contains: L-Glutathione (reduced) - 50 mg Other Ingredients: microcrystalline cellulose, vegetable cellulose, vegetable magnesium stearate Free from gluten, wheat, dairy, soy, yeast, sugar and sodium No artificial flavours, sweeteners, preservatives colour Precautions: Keep Solgar L-Glutathione out of reach of children
